In addition, the interleukin-1β inhibitor reduced hospitalization for heart failure (HHF) and the composite of HHF or heart failure-related mortality in patients with prior myocardial infarction and elevations in the high-sensitivity C-reactive protein [83]. This evidence concerns the gene CRP and heart failure.